The Series A round was co-led by Stage 2 Capital and AlbionVC to expand technical capabilities and international reach.
"Relocating is a messy amalgamation of 20-30 different processes that create a super stressful process during what should be one of the most exciting moments in someone’s life. There are support packages on the market to streamline relocation but these are often inflexible and expensive, costing companies thousands of pounds, and usually only available for those at the top of the company. By bringing all the processes into one platform, with great support at accessible price points, we help both the relocating employee with their move but also their employer provide a high value employee benefit."
Coretronic provided the investment alongside European family offices to support mass production ramp-up.
"Having industry heavyweight Coretronic on board as an investor and partner is further validation of both FlexEnable’s business model and our technology leadership in the materials and processes which enable volume production of unique flexible optical modules and displays. As a principal player in the LCD supply chain, Coretronic’s deep industry expertise will be a great benefit to us as we now move from production setup to mass production. We are very excited to have strong new investors on board, and very grateful for the on-going support from Rusnano and Novares, who have been instrumental in enabling us to develop our technology and great commercial projects over the past years."
The financing round was led by Collaborative Fund to support technology development and international expansion.
"2021 was a transformative year for Zoomo, as we saw enterprises and fleet managers, in addition to gig-workers, benefit from our innovative platform. 2022 is the year we take the business up a gear. The series B+ surplus funding will enable us to grow more aggressively across the globe, and ultimately put more efficient, safe and clean transport solutions on our roads."
The round was led by Deepbridge Capital to help manufacture trial units for a new urinary tract infection diagnostic device.
"FluoretiQ perfectly represents the type of highly innovative and growth-focused companies Deepbridge Capital is committed to supporting within the sector-specific Deepbridge Life Sciences EIS fund; a great example of the importance of the Enterprise Investment Scheme. Neciah has built a great team, eager to take on the significant challenge this market demands, and we are pleased to be working with them on this next exciting stage of their journey."
— Savvas Neophytou, Partner & Head of Life Sciences
The seed round was led by Maurice Ferre and Arjun Desai to accelerate growth across the UK, Europe and the US.
"TympaHealth can deliver ear and hearing health services safely into the community and away from the hospital, expanding critical access for patients. It is doing so effectively in the UK and it is great to see an NHS innovation taking the next step of their journey."
